As the use of chemotherapeutic agents increased rapidly in recent years, more patients are under the potential risk of chemotherapy related adverse reactions. Multiple regular exposures to the same drug by chemotherapy protocol may increase the risk of sensitization to a chemotherapeutic agent, which can result in hypersensitivity reactions. Once severe hypersensitivity reactions occur, causative drugs should be avoided. However, a substitute with equal efficacy is not always available. When there is no effective alternative, desensitization is a safe tool for maintenance of chemotherapeutic agents causing hypersensitivity reaction. In this review, we introduce the latest knowledge about desensitization protocol for chemotherapeutic agents which are frequently used recently. (Allergy Asthma Respir Dis 2013;1:295-302) 
항암제에 의한 과민반응 Table 4 . Grading of hypersensitivity reactions according to Common Terminology Criteria for Adverse Events v4.03 G1: Transient flushing or rash, drug fever < 38˚C; intervention not indicated G2: Intervention or infusion interruption indicated; responds promptly to symptomatic treatment (e.g., antihistamines, nonsteroidal anti-inflammatory drugs, narcotics); prophy lactic medications indicated for ≤ 24 hours G3: Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitaliza tion indicated for clinical sequelae (e.g., renal impairment, pulmonary infiltrates) -In case of anaphylaxis: Symptomatic bronchospasm, with or without urticaria; parenteral intervention indicated; allergy-related edema/angioedema; hypotension G4: Life-threatening consequences; urgent intervention indicated G5: Death 
